Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease.

This case highlights the importance of monitoring ACTH and corticotroph tumor size in patients with persistent CD, either under effective treatment with steroidogenesis inhibitors or after bilateral adrenalectomy.